Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Intravenous ferric carboxymaltose accelerates erythropoietic recovery from experimental malarial anemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3). GMZ2 formulated in Al(OH)3 has been tested in 3 published phase 1 clinical trials. The GMZ2/alum formulation showed good safety, tolerability, and immunogenicity, but whether antibodies elicited by vaccination are functional is not known.
Original languageEnglish
JournalThe Internet Journal of Infectious Diseases
Volume208
Issue number3
Pages (from-to)479-88
Number of pages10
ISSN1528-8366
DOIs
Publication statusPublished - 1 Aug 2013

    Research areas

  • Adjuvants, Immunologic, Adult, Aluminum Hydroxide, Antibodies, Protozoan, Child, Preschool, Humans, Immunoglobulin G, Malaria Vaccines, Malaria, Falciparum, Plasmodium falciparum, Vaccines, Synthetic

ID: 39017809